DK2154971T3 - Synergistisk farmaceutisk kombination til behandling af cancer - Google Patents

Synergistisk farmaceutisk kombination til behandling af cancer

Info

Publication number
DK2154971T3
DK2154971T3 DK07735911.5T DK07735911T DK2154971T3 DK 2154971 T3 DK2154971 T3 DK 2154971T3 DK 07735911 T DK07735911 T DK 07735911T DK 2154971 T3 DK2154971 T3 DK 2154971T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
pharmaceutical combination
synergistic pharmaceutical
synergistic
Prior art date
Application number
DK07735911.5T
Other languages
English (en)
Inventor
Maggie Rathos
Kalpana Joshi
Harshal Khanwalkar
Somesh Sharma
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Application granted granted Critical
Publication of DK2154971T3 publication Critical patent/DK2154971T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK07735911.5T 2007-05-15 2007-05-15 Synergistisk farmaceutisk kombination til behandling af cancer DK2154971T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2007/051841 WO2008139271A2 (en) 2007-05-15 2007-05-15 A synergistic pharmaceutical combination for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK2154971T3 true DK2154971T3 (da) 2012-04-02

Family

ID=40002696

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07735911.5T DK2154971T3 (da) 2007-05-15 2007-05-15 Synergistisk farmaceutisk kombination til behandling af cancer

Country Status (18)

Country Link
US (1) US8822526B2 (da)
EP (1) EP2154971B1 (da)
JP (1) JP5688288B2 (da)
KR (1) KR101403100B1 (da)
CN (1) CN101677567B (da)
AR (1) AR066564A1 (da)
AT (1) ATE538652T1 (da)
AU (1) AU2007353129B2 (da)
BR (1) BRPI0721626A2 (da)
CA (1) CA2687204C (da)
DK (1) DK2154971T3 (da)
ES (1) ES2380129T3 (da)
IL (1) IL202014A (da)
MX (1) MX2009012155A (da)
NZ (1) NZ581183A (da)
PT (1) PT2154971E (da)
TW (1) TWI449525B (da)
WO (1) WO2008139271A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461194B (zh) * 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
US9763982B2 (en) 2010-06-29 2017-09-19 The Regents Of The University Of California Depletion of cancer stem cells
US20120009203A1 (en) * 2010-06-29 2012-01-12 Anahid Jewett Depletion of cancer stem cells
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
KR20140014086A (ko) * 2010-11-19 2014-02-05 피라말 엔터프라이지즈 리미티드 파클리탁셀과 cdk 억제제의 약제학적 조합물
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
JP2014517063A (ja) 2011-06-24 2014-07-17 ピラマル エンタープライジーズ リミテッド ヒトパピローマウイルスと関連するがんを処置するための化合物
AR096892A1 (es) * 2013-07-12 2016-02-03 Piramal Entpr Ltd Una combinación farmacéutica para el tratamiento del melanoma
KR20180018507A (ko) 2015-04-20 2018-02-21 톨레로 파마수티컬스, 인크. 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측
MX2017014645A (es) 2015-05-18 2018-01-23 Tolero Pharmaceuticals Inc Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
WO2017024073A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
KR102494039B1 (ko) * 2016-03-28 2023-01-30 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US20230133972A1 (en) * 2017-04-04 2023-05-04 University Of Miami Biomarkers indicative of prostate cancer and treatment thereof
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
CA3093548A1 (en) * 2018-03-12 2020-01-23 Yeditepe Universitesi A chemotherapeutic agent comprising a combination of alexidine dihydrochloride and sodium pentaborate pentahydrate
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
RU2710273C1 (ru) * 2019-04-24 2019-12-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Фармацевтическая композиция для лечения злокачественных новообразований
CN114767669B (zh) * 2022-05-20 2023-07-04 湖南省中医药研究院 一种P-gp抑制剂及其提取方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915301B2 (en) * 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
TWI331034B (en) * 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7884127B2 (en) * 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
BR0316004A (pt) * 2002-11-06 2005-09-13 Cyclacel Ltd Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
BRPI0416870A (pt) * 2003-12-08 2007-01-30 Univ Arizona composições anticáncer sinergìticas
JP2008533039A (ja) * 2005-03-11 2008-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 抗アポトーシスＢｃｌ−２ファミリーメンバーのクロメン−４−オン阻害剤およびその使用

Also Published As

Publication number Publication date
TW200913991A (en) 2009-04-01
IL202014A0 (en) 2010-06-16
CN101677567B (zh) 2013-06-19
BRPI0721626A2 (pt) 2013-01-22
KR20100017763A (ko) 2010-02-16
EP2154971B1 (en) 2011-12-28
MX2009012155A (es) 2010-01-15
US8822526B2 (en) 2014-09-02
US20100305057A1 (en) 2010-12-02
AR066564A1 (es) 2009-08-26
WO2008139271A3 (en) 2009-04-23
EP2154971A2 (en) 2010-02-24
JP5688288B2 (ja) 2015-03-25
ATE538652T1 (de) 2012-01-15
CN101677567A (zh) 2010-03-24
CA2687204C (en) 2015-11-24
AU2007353129A1 (en) 2008-11-20
EP2154971A4 (en) 2010-05-19
TWI449525B (zh) 2014-08-21
CA2687204A1 (en) 2008-11-20
KR101403100B1 (ko) 2014-06-19
ES2380129T3 (es) 2012-05-08
WO2008139271A2 (en) 2008-11-20
AU2007353129B2 (en) 2014-02-20
PT2154971E (pt) 2012-04-10
NZ581183A (en) 2012-03-30
IL202014A (en) 2014-06-30
JP2010526862A (ja) 2010-08-05

Similar Documents

Publication Publication Date Title
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK3289876T3 (da) Forbindelser til behandling af cancer
HK1224200A1 (zh) 用於治療胰腺癌的藥物
DK2121139T3 (da) Formulations for cancer treatment
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK3567035T3 (da) N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0813670A2 (pt) Compostos para tratamento
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
DK2216021T3 (da) Farmaceutisk sammensætning til behandling af overaktiv blære
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
DK2063881T3 (da) Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer
DK2173831T3 (da) Brøndbehandling
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
DK2022504T3 (da) Salve til behandling af hæmorider
BRPI0818598A2 (pt) agentes terapêuticos - 802
BRPI0810207A2 (pt) Métodos e composições para o tratamento de câncer
DK2285416T3 (da) Konjugat til behandlingen af mesotheliom